Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
J Clin Endocrinol Metab. 2011 May;96(5):1237-45. doi: 10.1210/jc.2010-2359. Epub 2011 Feb 23.
Medullary thyroid carcinoma (MTC) is diagnosed only after thyroidectomy in approximately 10-15% of cases. This delay in diagnosis can have adverse consequences such as missing underlying pheochromocytoma or hyperparathyroidism in unrecognized multiple endocrine neoplasia type 2 and choosing a suboptimal extent of surgery. Barriers to accurate preoperative diagnosis and management strategies after the discovery of occult MTC are reviewed.
We reviewed PubMed (1975-September 2010) using the search terms medullary carcinoma, calcitonin, multinodular goiter, Graves' disease, calcium/diagnostic use, and pentagastrin/diagnostic use.
The combined prevalence of occult MTC in thyroidectomy series is approximately 0.3%. Routine calcitonin measurement in goiter patients identifies C-cell hyperplasia as well as MTC. Challenges include interpreting intermediate values and unavailability of pentagastrin stimulation testing in the United States. Early studies have begun to identify appropriate cutoff values for calcium-stimulated calcitonin. For management of incidentally discovered MTC, we highlight the role of early measurement of calcitonin and carcinoembryonic antigen, RET testing, and comprehensive neck ultrasound exam to direct further imaging, completion thyroidectomy, and lymph node dissection.
Occult MTC is an uncommon, but clinically significant entity. If calcium stimulation testing cutoff data become well-validated, calcitonin screening would likely become more widely accepted in the diagnostic work-up for thyroid nodules in the United States. Among patients with incidental MTC, those with persistently elevated serum calcitonin levels, positive RET test, or nodal disease are good candidates for completion thyroidectomy and lymph node dissection in selected cases, whereas patients with undetectable calcitonin, negative RET testing, and no sonographic abnormalities often may be watched conservatively.
大约有 10%-15%的病例是在甲状腺切除术后才诊断出甲状腺髓样癌(MTC)。这种诊断的延迟可能会导致不良后果,例如在未被识别的多发性内分泌肿瘤 2 型中错过潜在的嗜铬细胞瘤或甲状旁腺功能亢进,以及选择手术范围不理想。本文回顾了隐匿性 MTC 发现后准确的术前诊断和管理策略。
我们通过搜索术语“髓样癌、降钙素、多结节性甲状腺肿、格雷夫斯病、钙/诊断用途和五肽胃泌素/诊断用途”,在 PubMed(1975 年-2010 年 9 月)上进行了回顾。
在甲状腺切除术系列中,隐匿性 MTC 的综合患病率约为 0.3%。在甲状腺肿患者中常规测量降钙素可识别 C 细胞增生和 MTC。挑战包括解释中间值以及在美国无法进行五肽胃泌素刺激试验。早期研究已经开始确定钙刺激降钙素的适当临界值。对于偶然发现的 MTC 的管理,我们强调了早期测量降钙素和癌胚抗原、RET 检测以及全面的颈部超声检查以指导进一步的成像、完成甲状腺切除术和淋巴结清扫的作用。
隐匿性 MTC 是一种不常见但具有临床意义的实体。如果钙刺激测试截止值数据得到充分验证,那么在美国,降钙素筛查很可能会在甲状腺结节的诊断评估中得到更广泛的接受。在偶然发现的 MTC 患者中,那些血清降钙素水平持续升高、RET 检测阳性或有淋巴结疾病的患者是在某些情况下完成甲状腺切除术和淋巴结清扫的良好候选者,而那些降钙素检测不可测、RET 检测阴性且无超声异常的患者通常可以保守观察。